Stroke and Vascular Neurology (Sep 2020)

Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population

  • Liping Liu,
  • Kangning Chen,
  • Yilong Wang,
  • Zhongrong Miao,
  • Yuan Gao,
  • Yuming Xu,
  • Wei Liu,
  • Benyan Luo,
  • Bin Peng,
  • Yong Huo,
  • Qiang Dong,
  • Zixiao Li,
  • Xingquan Zhao,
  • Jizong Zhao,
  • Wei Wang,
  • Bin Jiang,
  • Shuo Wang,
  • Chen Wang,
  • Linong Ji,
  • Shizheng Wu,
  • Yong Jiang,
  • Wenzhi Wang,
  • Yapeng Li,
  • Xiaomeng Yang,
  • Junbo Ge,
  • Xunming Ji,
  • Tong Zhang,
  • Li He Li Guo,
  • Tielin Li,
  • Ning Wang,
  • Peng Xie,
  • Yun Xu,
  • Jinsheng Zeng,
  • Chaodong Zhang,
  • Zhuo Zhang,
  • Gang Zhao,
  • Dongling Sun,
  • Haixin Sun,
  • Xiaojuan Ru,
  • Penglian Wang,
  • Lixia Zong,
  • Yuyuan Xu,
  • Xiaoyuan Niu,
  • Dingfeng Su,
  • Beisha Tang,
  • Haiqiang Qin,
  • Lei Guo,
  • Shangrong Han,
  • Yong Cao,
  • Ling Guan,
  • Qian Jia,
  • Yuming Jiao,
  • Shuya Li,
  • Xuewei Xie,
  • Yingying Yang,
  • Mengyuan Zhou

DOI
https://doi.org/10.1136/svn-2020-000385
Journal volume & issue
Vol. 5, no. 3

Abstract

Read online

Aim Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population.Methods Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke.Results This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence.Conclusions This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.